GlassScriptPhysician profile
Samantha Simpson
NPI 1407417165
$463.45
in general payments reported to CMS, 2019-2025
11 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.82 · 2023: $40.88 · 2024: $40.97 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $144.16 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $57.24 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $51.96 | 2025 | Fanapt |
| Lilly USA, LLC | $40.80 | 2021-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $35.51 | 2025 | Spravato |
| Abbvie INC. | $31.26 | 2023-2024 | |
| Lundbeck LLC | $27.78 | 2025 | Rexulti |
| Sandoz INC. | $23.72 | 2024 | Hyrimoz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.77 | 2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $17.36 | 2025 | |
| Pfizer INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.